Compare CAPT & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAPT | ABP |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 12.5M |
| IPO Year | N/A | N/A |
| Metric | CAPT | ABP |
|---|---|---|
| Price | $0.39 | $4.10 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 13.9K |
| Earning Date | 01-01-0001 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,389,944.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 84.70 | 50.00 |
| 52 Week Low | $0.30 | $3.78 |
| 52 Week High | $1.94 | $42.90 |
| Indicator | CAPT | ABP |
|---|---|---|
| Relative Strength Index (RSI) | 41.81 | 39.37 |
| Support Level | $0.36 | $3.98 |
| Resistance Level | $0.58 | $5.09 |
| Average True Range (ATR) | 0.07 | 0.37 |
| MACD | 0.02 | -0.08 |
| Stochastic Oscillator | 33.94 | 20.23 |
Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.